execute this the and for we our afternoon for since where you us. first has been call, strategy, last thank it only you of Good detailed to believe joining accelerate with growth about XXXX, FPC continue quarter in In against potential six reputation from call earnings short. will of the keep we our Since our we business high we weeks our disease states. solid multiple strategy from by and strength are platform growth dialysis to therapeutics generated the combining our foundation, what
Our the to concentrates of the dialysis business, base continue sales steadily of is which perform.
this us second are the to of foundation grow. and a haemodialysis and supplier in million solid on We revenue annual in United generates business States about the gives concentrates $XX which largest
the of in lower compared fourth in the to market XXXX. U.S. Triferic sales Our quarter dialysis for net were QX
three sales which implementation. QX quarter-over-quarter. in preparation clinics While date. made to under changes. discontinue had contracted patients actively that the increased, three new of The strongest of dialysis to due purchases net flat acquisition or to We of large clinics period where QX each was went Triferic number was with use number clinics organizations, XXXX customers independent our contract for management of treating
all in and delays were there occur not did implementation three repurchases However, cases in in QX.
patients ramping was launched on QX of February. and AVNU, in in putting Triferic see of commercially We up from are as expecting formulation our some begin to Triferic reorders clinics therapy. IV these they
it difficult dialysis the session. found expect we before, a labor IV As at of said delivering requirement we have to clinics slow each slower accommodate have a as infusion uptake
will We and clinics data and are we utilize the anemia to and savings. customers going cost stable later payment forward present expect hemoglobin, environment believe of conscious we make seeing we challenges reduced as our interventions other capitated are with exploring this to in options year. dialysis, faced Triferic drugs adoption increase second to the have cost to resulting we of the half. progress alternative in methods more results, readout The continue IV Triferic have real-world administration that with actively Despite the positive
are remaining program, FPC infusion FPC are To to products result, I'll we critical foundational expect pivot many and for more helping that catalyst given patient data and growth which and technology. future medical population, pharmaceutical the evidence X.X for are as on a our platform large potentially growth loyal doses we comments has These a FPC the have generated states customers based as haemodialysis than on efficacy a in extensive my developing to Our Rockwell been success. our date our home very real-world that be the will safety outside of Today, are data by us million focus major generate frail dialysis. opportunity. disease
iron select Our is significant unmet patients A deficiency for receiving anemia at home. effective safe infusion development our therapies and decision strategic treatment to home area as need is a priority one. intravenous for a
dialysis the make setting. of use patients. intensify. I for Based you're patients safety in to population the given home As the years my development with trying seen the to the experience fortunate more dialysis database we're we de-risks events. development, molecule that on with and date treated from in plus its home, these product believe our in in treating believe drug trials, ideal experience XX Based for efficacy significantly of and FPC setting. reliable about a clinical infusion FPC candidate in your its million serious excellent on have FPC studying. in being use the will safety to of its data, effectiveness you're the need a we more than the learn believe We efficacy safety we're it and safety no patient an assessing Typically are With of doses have patients more that large and safety clinical to
we iron underlying Many And products suffer clinic no the believe and setting. regarding infusion reduced. there's trials. health infusions actively safety the that with as favorable can It's deficiency, case the know home anemia, older cause diseases policies the a the safely not patient is FPC FPC is issue disease of setting. Likewise, have matter home in unexpected that infusion efficacy, diseases. a be increasing we setting. to and chronic from This Both an or of insurers is the another patient's home high expensive accelerating of home given presence hospital and deficiency home are for to demonstrate is is home give home the long risk iron therapies use setting the a in growing not in effect Cost So is that The the respect infusion in where reimbursement ability to much improve of influenced patient bleeding. This the the treatments driven IVR other is particularly by with to Medicare growth saving driver anemia. significantly de-risked are setting infusion. of long safety and to inflammation. for growth substantially X private give most therapies incidence you the in condition by of state, means that the dose by very intravenous being in the number and technologies compared Phase of drugs number for for new as requiring of allow associated a an groups the that given infusion of efficacy
prescribing generally infusions practices This vicious forms up required, or for for infusion deficiency. of for the the iron frequent difficult IV under-diagnosis visits medicines under-treatment for Importantly, infusion can most physicians do cycle who of results home of a in are not patients. and parental and set iron nutrients be office have home other
can iron immune of increased potential the including note the than fusion at patients higher be is be X% deficiency Contrast this heart iron business example, than in point. of dialysis. population, any Home iron failure. consequences home of much serious for deficiency remain parental anemia have half it's portfolio dialysis nutrition For an deficient. has the important with iron to if less fatigue, and a risk which of where And patients to risk high also at compromise, margin deficiency and our the product extreme function left untreated, FPC population,
and infusion product insurance, commercial FPC reimbursement. As for meet that has and would The we be IVA B a dialysis, for eligible for diverse, pricing. and the home and if future infusion product, separate for from believe Medicare private means that then FPC be will treatment that and our application proposed submission. setting and well may This current that for Part reimbursement, criteria allowing home we positioned the new for submit confirmed drug a public for products based FDA would the approved the be would private public distinct appropriate XXX(b)(X) which
product the the $XXX appropriate we estimate to in of U.S. this With and the market the up in secure considering addressable suitability ability opportunity area, to million. total pricing of
outcome We expect thereafter Phase to randomized have be first trial This start to FDA X later well-controlled the our clinical pending with shortly of trial trial will a to look year. and this product progress. the meeting successful you the With I'll our for treatment updating I patients the forward call a of that we overview. Russell financial Skibsted for brief Russell? home in iron turn infusion. anemia any undergoing as to pre-IND
